Chemokines in atherosclerosis: Proceedings resumed

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 4, 2014, Pages 742-750

  Zernecke, Alma ^a,b,c   Weber, Christian ^c,d,e  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

Author keywords

atherosclerosis; chemokine; chemokines; inflammation; leukocytes; receptors

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CXCL16 CHEMOKINE; LOW DENSITY LIPOPROTEIN RECEPTOR; LYSOPHOSPHATIDIC ACID; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MIGRATION INHIBITION FACTOR; RANTES; STROMAL CELL DERIVED FACTOR 1;

ADOPTIVE TRANSFER; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BONE MARROW CELL; CAROTID ARTERY; CELL TYPE; ENDOTHELIUM CELL; FOAM CELL; HEMATOPOIETIC CELL; HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; LEUKOCYTE; LIPID DIET; MACROPHAGE; MACROPHAGE MIGRATION; MICROSCOPY; MONOCYTE; MUSCLE CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SMOOTH MUSCLE FIBER; TH17 CELL; VASCULITIS;

ATHEROSCLEROSIS; CHEMOKINES; INFLAMMATION; LEUKOCYTES; RECEPTORS, CHEMOKINE;

ANIMALS; ATHEROSCLEROSIS; BLOOD VESSELS; CHEMOKINES; CHEMOTAXIS, LEUKOCYTE; HUMANS; INFLAMMATION; MONOCYTES; NEUTROPHIL INFILTRATION; NEUTROPHILS; RECEPTORS, CHEMOKINE; SIGNAL TRANSDUCTION;

EID: 84897039407     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.301655     Document Type: Review

References (79)

1. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011;17:1410-1422.
2. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol. 2008;8:802-815.
3. Zernecke A, Shagdarsuren E, Weber C. Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol. 2008;28:1897-1908.
4. Weber C, Schober A, Zernecke A. Chemokines: key regulators of mono-nuclear cell recruitment in atherosclerotic vascular disease. Arterioscler Thromb Vasc Biol. 2004;24:1997-2008.
5. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science. 2010;327:656-661.
6. Yona S, Kim KW, Wolf Y, Mildner A, Varol D, Breker M, Strauss-Ayali D, Viukov S, Guilliams M, Misharin A, Hume DA, Perlman H, Malissen B, Zelzer E, Jung S. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity. 2013;38:79-91.
7. Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myo-cardial infarction, and heart failure. Science. 2013;339:161-166.
8. Drechsler M, Megens RT, van Zandvoort M, Weber C, Soehnlein O. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation. 2010;122:1837-1845.
9. Soehnlein O, Drechsler M, Döring Y, et al. Distinct functions of chemo-kine receptor axes in the atherogenic mobilization and recruitment of classical monocytes. EMBO Mol Med. 2013;5:471-481.
10. Zhou Z, Subramanian P, Sevilmis G, Globke B, Soehnlein O, Karshovska E, Megens R, Heyll K, Chun J, Saulnier-Blache JS, Reinholz M, van Zandvoort M, Weber C, Schober A. Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium. Cell Metab. 2011;13:592-600.
11. Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J, Garin A, Liu J, Mack M, van Rooijen N, Lira SA, Habenicht AJ, Randolph GJ. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest. 2007;117:185-194.
12. Serbina NV, Pamer EG. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol. 2006;7:311-317.
13. Kennedy A, Gruen ML, Gutierrez DA, Surmi BK, Orr JS, Webb CD, Hasty AH. Impact of macrophage infammatory protein-1α defciency on atherosclerotic lesion formation, hepatic steatosis, and adipose tissue expansion. PLoS One. 2012;7:e31508.
14. de Jager SC, Bot I, Kraaijeveld AO, Korporaal SJ, Bot M, van Santbrink PJ, van Berkel TJ, Kuiper J, Biessen EA. Leukocyte-specifc CCL3 def-ciency inhibits atherosclerotic lesion development by affecting neutrophil accumulation. Arterioscler Thromb Vasc Biol. 2013;33:e75-e83.
15. Zernecke A, Liehn EA, Gao JL, Kuziel WA, Murphy PM, Weber C. Defciency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10. Blood. 2006;107: 4240-4243.
16. Zernecke A, Schober A, Bot I, von Hundelshausen P, Liehn EA, Möpps B, Mericskay M, Gierschik P, Biessen EA, Weber C. SDF-1alpha/CXCR4 axis is instrumental in neointimal hyperplasia and recruitment of smooth muscle progenitor cells. Circ Res. 2005;96:784-791.
17. Doran AC, Lipinski MJ, Oldham SN, et al. B-cell aortic homing and ath-eroprotection depend on Id3. Circ Res. 2012;110:e1-e12.
18. Trogan E, Feig JE, Dogan S, Rothblat GH, Angeli V, Tacke F, Randolph GJ, Fisher EA. Gene expression changes in foam cells and the role of chemo-kine receptor CCR7 during atherosclerosis regression in ApoE-defcient mice. Proc Natl Acad Sci USA. 2006;103:3781-3786.
19. Feig JE, Rong JX, Shamir R, Sanson M, Vengrenyuk Y, Liu J, Rayner K, Moore K, Garabedian M, Fisher EA. HDL promotes rapid atherosclerosis regression in mice and alters infammatory properties of plaque monocyte-derived cells. Proc Natl Acad Sci USA. 2011;108:7166-7171.
20. Feig JE, Shang Y, Rotllan N, Vengrenyuk Y, Wu C, Shamir R, Torra IP, Fernandez-Hernando C, Fisher EA, Garabedian MJ. Statins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophages. PLoS One. 2011;6:e28534.
21. Potteaux S, Gautier EL, Hutchison SB, van Rooijen N, Rader DJ, Thomas MJ, Sorci-Thomas MG, Randolph GJ. Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/-mice during disease regression. J Clin Invest. 2011;121:2025-2036.
22. Wan W, Lionakis MS, Liu Q, Roffê E, Murphy PM. Genetic deletion of chemokine receptor Ccr7 exacerbates atherogenesis in ApoE-defcient mice. Cardiovasc Res. 2013;97:580-588.
23. Luchtefeld M, Grothusen C, Gagalick A, Jagavelu K, Schuett H, Tietge UJ, Pabst O, Grote K, Drexler H, Förster R, Schieffer B. Chemokine receptor 7 knockout attenuates atherosclerotic plaque development. Circulation. 2010;122:1621-1628.
24. Eriksson EE. Intravital microscopy on atherosclerosis in apolipoprotein e-defcient mice establishes microvessels as major entry pathways for leukocytes to advanced lesions. Circulation. 2011;124:2129-2138.
25. Koenen RR, von Hundelshausen P, Nesmelova IV, Zernecke A, Liehn EA, Sarabi A, Kramp BK, Piccinini AM, Paludan SR, Kowalska MA, Kungl AJ, Hackeng TM, Mayo KH, Weber C. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med. 2009;15:97-103.
26. Rousselle A, Qadri F, Leukel L, Yilmaz R, Fontaine JF, Sihn G, Bader M, Ahluwalia A, Duchene J. CXCL5 limits macrophage foam cell formation in atherosclerosis. J Clin Invest. 2013;123:1343-1347.
27. Weber C, Meiler S, Döring Y, et al. CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice. J Clin Invest. 2011;121:2898-2910.
28. Bernhagen J, Krohn R, Lue H, et al. MIF is a noncognate ligand of CXC chemokine receptors in infammatory and atherogenic cell recruitment. Nat Med. 2007;13:587-596.
29. Li X, Zhu M, Penfold M, Koenen RR, Thiemann A, Heyll K, Akhtar S, Koyadan S, Wu Z, Gremse F, Kiessling F, van Zandvoort MA, Schall TA, Weber C, Schober A. Activation of cxcr7 limits atherosclerosis and improves hyperlipidemia by increasing cholesterol uptake in adipose tissue [published online ahead of print December 27, 2013]. Circulation. doi: 10.1161/CIRCULATIONAHA.113.006840. http://circ.ahajournals. org/content/early/2013/12/27/CIRCULATIONAHA.113.006840. abstract. Accessed January 23, 2014.
30. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, Hristov M, Koppel T, Jahantigh MN, Lutgens E, Wang S, Olson EN, Schober A, Weber C. Delivery of microrna-126 by apoptotic bodies induces cxcl12-dependent vascular protection. Sci Signal. 2009:2:ra81.
31. Akhtar S, Gremse F, Kiessling F, Weber C, Schober A. CXCL12 promotes the stabilization of atherosclerotic lesions mediated by smooth muscle progenitor cells in Apoe-defcient mice. Arterioscler Thromb Vasc Biol. 2013;33:679-686.
32. Landsman L, Bar-On L, Zernecke A, Kim KW, Krauthgamer R, Shagdarsuren E, Lira SA, Weissman IL, Weber C, Jung S. CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood. 2009;113:963-972.
33. Poupel L, Boissonnas A, Hermand P, Dorgham K, Guyon E, Auvynet C, Charles FS, Lesnik P, Deterre P, Combadiere C. Pharmacological inhibition of the chemokine receptor, CX3CR1, reduces atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2013;33:2297-2305.
34. Postea O, Vasina EM, Cauwenberghs S, Projahn D, Liehn EA, Lievens D, Theelen W, Kramp BK, Butoi ED, Soehnlein O, Heemskerk JW, Ludwig A, Weber C, Koenen RR. Contribution of platelet CX(3)CR1 to platelet-monocyte complex formation and vascular recruitment during hyperlipidemia. Arterioscler Thromb Vasc Biol. 2012;32:1186-1193.
35. Butoi ED, Gan AM, Manduteanu I, Stan D, Calin M, Pirvulescu M, Koenen RR, Weber C, Simionescu M. Cross talk between smooth muscle cells and mono-cytes/activated monocytes via CX3CL1/CX3CR1 axis augments expression of pro-Atherogenic molecules. Biochim Biophys Acta. 2011;1813:2026-2035.
36. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/-mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998;394:894-897.
37. Nazari-Jahantigh M, Wei Y, Noels H, Akhtar S, Zhou Z, Koenen RR, Heyll K, Gremse F, Kiessling F, Grommes J, Weber C, Schober A. MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macro-phages. J Clin Invest. 2012;122:4190-4202.
38. Goossens P, Gijbels MJ, Zernecke A, Eijgelaar W, Vergouwe MN, van der Made I, Vanderlocht J, Beckers L, Buurman WA, Daemen MJ, Kalinke U, Weber C, Lutgens E, de Winther MP. Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. Cell Metab. 2010;12:142-153.
39. Potteaux S, Combadière C, Esposito B, Casanova S, Merval R, Ardouin P, Gao JL, Murphy PM, Tedgui A, Mallat Z. Chemokine receptor CCR1 disruption in bone marrow cells enhances atherosclerotic lesion development and infammation in mice. Mol Med. 2005;11:16-20.
40. Braunersreuther V, Zernecke A, Arnaud C, Liehn EA, Steffens S, Shagdarsuren E, Bidzhekov K, Burger F, Pelli G, Luckow B, Mach F, Weber C. Ccr5 but not Ccr1 defciency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2007;27:373-379.
41. Wan W, Murphy PM. Regulation of atherogenesis by chemokine receptor CCR6. Trends Cardiovasc Med. 2011;21:140-144.
42. Wan W, Lim JK, Lionakis MS, Rivollier A, McDermott DH, Kelsall BL, Farber JM, Murphy PM. Genetic deletion of chemokine receptor Ccr6 decreases atherogenesis in ApoE-defcient mice. Circ Res. 2011;109:374-381.
43. Manthey HD, Cochain C, Barnsteiner S, Karshovska E, Pelisek J, Koch M, Chaudhari SM, Busch M, Eckstein HH, Weber C, Koenen RR, Zernecke A. CCR6 selectively promotes monocyte mediated infammation and atherogenesis in mice. Thromb Haemost. 2013;110:1267-1277.
44. Moos MP, John N, Gräbner R, Nossmann S, Günther B, Vollandt R, Funk CD, Kaiser B, Habenicht AJ. The lamina adventitia is the major site of immune cell accumulation in standard chow-fed apolipoprotein E-defcient mice. Arterioscler Thromb Vasc Biol. 2005;25:2386-2391.
45. Döring Y, Soehnlein O, Drechsler M, Shagdarsuren E, Chaudhari SM, Meiler S, Hartwig H, Hristov M, Koenen RR, Hieronymus T, Zenke M, Weber C, Zernecke A. Hematopoietic interferon regulatory factor 8-defciency accelerates atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2012;32:1613-1623.
46. Zernecke A, Bernhagen J, Weber C. Macrophage migration inhibitory factor in cardiovascular disease. Circulation. 2008;117:1594-1602.
47. Simons D, Grieb G, Hristov M, Pallua N, Weber C, Bernhagen J, Steffens G. Hypoxia-induced endothelial secretion of macrophage migration inhibitory factor and role in endothelial progenitor cell recruitment. J Cell Mol Med. 2011;15:668-678.
48. Kraemer S, Lue H, Zernecke A, Kapurniotu A, Andreetto E, Frank R, Lennartz B, Weber C, Bernhagen J. MIF-chemokine receptor interactions in atherogenesis are dependent on an N-loop-based 2-site binding mechanism. FASEB J. 2011;25:894-906.
49. Weber C, Kraemer S, Drechsler M, Lue H, Koenen RR, Kapurniotu A, Zernecke A, Bernhagen J. Structural determinants of MIF functions in CXCR2-mediated infammatory and atherogenic leukocyte recruitment. Proc Natl Acad Sci USA. 2008;105:16278-16283.
50. Müller I, Schönberger T, Schneider M, et al. Gremlin-1 is an inhibitor of macrophage migration inhibitory factor and attenuates atherosclerotic plaque growth in ApoE-/-Mice. J Biol Chem. 2013;288:31635-31645.
51. Stark K, Eckart A, Haidari S, Tirniceriu A, Lorenz M, von Brühl ML, Gärtner F, Khandoga AG, Legate KR, Pless R, Hepper I, Lauber K, Walzog B, Massberg S. Capillary and arteriolar pericytes attract innate leukocytes exiting through venules and 'instruct' them with pattern-recognition and motility programs. Nat Immunol. 2013;14:41-51.
52. von Hundelshausen P, Petersen F, Brandt E. Platelet-derived chemokines in vascular biology. Thromb Haemost. 2007;97:704-713.
53. Weber C, Koenen RR. Fine-tuning leukocyte responses: towards a chemo-kine 'interactome'. Trends Immunol. 2006;27:268-273.
54. Gouwy M, Schiraldi M, Struyf S, Van Damme J, Uguccioni M. Possible mechanisms involved in chemokine synergy fne tuning the infammatory response. Immunol Lett. 2012;145:10-14.
55. Springael JY, Urizar E, Parmentier M. Dimerization of chemokine receptors and its functional consequences. Cytokine Growth Factor Rev. 2005;16:611-623.
56. Aslanian AM, Charo IF. Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis. Circulation. 2006;114:583-590.
57. Gleissner CA, Shaked I, Little KM, Ley K. CXC chemokine ligand 4 induces a unique transcriptome in monocyte-derived macrophages. J Immunol. 2010;184:4810-4818.
58. Heiseke AF, Faul AC, Lehr HA, Förster I, Schmid RM, Krug AB, Reindl W. CCL17 promotes intestinal infammation in mice and counteracts regulatory T cell-mediated protection from colitis. Gastroenterology. 2012;142:335-345.
59. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol. 2000;18:593-620.
60. Mantovani A, Bonecchi R, Locati M. Tuning infammation and immunity by chemokine sequestration: decoys and more. Nat Rev Immunol. 2006;6:907-918.
61. Cochain C, Auvynet C, Poupel L, et al. The chemokine decoy receptor D6 prevents excessive infammation and adverse ventricular remodeling after myocardial infarction. Arterioscler Thromb Vasc Biol. 2012;32:2206-2213.
62. Novitzky-Basso I, Rot A. Duffy antigen receptor for chemokines and its involvement in patterning and control of infammatory chemokines. Front Immunol. 2012;3:266.
63. Naumann U, Cameroni E, Pruenster M, Mahabaleshwar H, Raz E, Zerwes HG, Rot A, Thelen M. CXCR7 functions as a scavenger for CXCL12 and CXCL11. PLoS One. 2010;5:e9175.
64. Zabel BA, Wang Y, Lewén S, Berahovich RD, Penfold ME, Zhang P, Powers J, Summers BC, Miao Z, Zhao B, Jalili A, Janowska-Wieczorek A, Jaen JC, Schall TJ. Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands. J Immunol. 2009;183:3204-3211.
65. Rajagopal S, Kim J, Ahn S, Craig S, Lam CM, Gerard NP, Gerard C, Lefkowitz RJ. Beta-Arrestin-but not G protein-mediated signaling by the "decoy" receptor CXCR7. Proc Natl Acad Sci USA. 2010;107:628-632.
66. Rosenkilde MM. Virus-encoded chemokine receptors-putative novel antiviral drug targets. Neuropharmacology. 2005;48:1-13.
67. Rosenkilde MM, Smit MJ, Waldhoer M. Structure, function and physiological consequences of virally encoded chemokine seven transmembrane receptors. Br J Pharmacol. 2008;153 (suppl 1):S154-S166.
68. Maussang D, Vischer HF, Leurs R, Smit MJ. Herpesvirus-encoded G protein-coupled receptors as modulators of cellular function. Mol Pharmacol. 2009;76:692-701.
69. Zhou YF, Leon MB, Waclawiw MA, Popma JJ, Yu ZX, Finkel T, Epstein SE. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med. 1996;335:624-630.
70. Streblow DN, Kreklywich CN, Smith P, Soule JL, Meyer C, Yin M, Beisser P, Vink C, Nelson JA, Orloff SL. Rat cytomegalovirus-Accel-erated transplant vascular sclerosis is reduced with mutation of the chemokine-receptor R33. Am J Transplant. 2005;5:436-442.
71. Veillard NR, Kwak B, Pelli G, Mulhaupt F, James RW, Proudfoot AE, Mach F. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res. 2004;94:253-261.
72. Braunersreuther V, Steffens S, Arnaud C, Pelli G, Burger F, Proudfoot A, Mach F. A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice. Arterioscler Thromb Vasc Biol. 2008;28:1090-1096.
73. van Wanrooij EJ, Happé H, Hauer AD, de Vos P, Imanishi T, Fujiwara H, van Berkel TJ, Kuiper J. HIV entry inhibitor TAK-779 attenuates ath-erogenesis in low-density lipoprotein receptor-defcient mice. Arterioscler Thromb Vasc Biol. 2005;25:2642-2647.
74. Copin JC, da Silva RF, Fraga-Silva RA, et al. Treatment with Evasin-3 reduces atherosclerotic vulnerability for ischemic stroke, but not brain injury in mice. J Cereb Blood Flow Metab. 2013;33:490-498.
75. Proudfoot AE, Power CA, Schwarz MK. Anti-chemokine small molecule drugs: a promising future? Expert Opin Investig Drugs. 2010;19:345-355.
76. Schall TJ, Proudfoot AE. Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nat Rev Immunol. 2011;11:355-363.
77. Cipriani S, Francisci D, Mencarelli A, Renga B, Schiaroli E, D'Amore C, Baldelli F, Fiorucci S. Effcacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. Circulation. 2013;127:2114-2124.
78. Wiesner P, Tafelmeier M, Chittka D, Choi SH, Zhang L, Byun YS, Almazan F, Yang X, Iqbal N, Chowdhury P, Maisel A, Witztum JL, Handel TM, Tsimikas S, Miller YI. MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma. J Lipid Res. 2013;54:1877-1883.
79. Robbins CS, Hilgendorf I, Weber GF, et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med. 2013;19:1166-1172.